Holdings
Fairmount Funds Management LLC
As of Sep 30, 2026, Fairmount Funds Management LLC reported 10 positions worth US$1.12B. Largest: Oruka Therapeutics, Inc., Dianthus Therapeutics, Inc. and Cogent Biosciences, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Oruka Therapeutics, Inc. | 3.71M | US$309M | no change | Sep 30, 2026 |
| Dianthus Therapeutics, Inc. | 2.54M | US$223M | no change | Sep 30, 2026 |
| Cogent Biosciences, Inc. | 5.5M | US$176M | no change | Sep 30, 2026 |
| Viridian Therapeutics, Inc. | 5.09M | US$105M | no change | Sep 30, 2026 |
| Enliven Therapeutics, Inc. | 1.86M | US$85.1M | no change | Sep 30, 2026 |
| Jade Biosciences, Inc. | 4.55M | US$64M | no change | Sep 30, 2026 |
| Zenas BioPharma, Inc. | 2.37M | US$64M | +12,333 | Sep 30, 2026 |
| Crescent Biopharma, Inc. | 3.6M | US$52.5M | +853K | Sep 30, 2026 |
| Sensei Biotherapeutics, Inc. | 722K | US$21.5M | no change | Sep 30, 2026 |
| Inhibikase Therapeutics, Inc. | 8.63M | US$17.7M | no change | Sep 30, 2026 |